Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPAZ-1 litifilimab in active systemic lupus erythematosus
2023-505695-30-00Phase 3Authorised
- Sponsor
- Biogen
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Litifilimab plus background nonbiologic standard of care with Placebo plus background nonbiologic standard of care (2 arms). Primary endpoint: SRI-4 response at Week 52. Planned start Nov 2021; status: authorised.
02
Drugs
litifilimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2023-505695-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505695-30-00.